Skip to main content

Hims & Hers Health, Inc. (HIMS) Stock Analysis

Catalyst-Driven edge

HoldVALUE-TRAP 3/5High Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Hold if already holding. Not a fresh buy at $26.41, but acceptable to hold if already in. Reasons: Concentration risk — Product: subscription prescription products; Analyst target reached - limited upside remaining.

Hims and Hers operates a consumer telehealth platform connecting patients to licensed providers for prescription medications and wellness products across sexual health, hair loss, weight loss, dermatology, and mental health. Revenue reached 2,347.6M in 2025, driven primarily by... Read more

$26.41+18.1% A.UpsideScore 4.5/10#27 of 29 Drug Manufacturers - Specialty & Generic
Stop $24.58Target $31.22(resistance)A.R:R -0.9:1
Analyst target$26.25-0.6%14 analysts
$31.22our TP
$26.41price
$26.25mean
$18
$35

Hold if already holding. Not a fresh buy at $26.41, but acceptable to hold if already in. Reasons: Concentration risk — Product: subscription prescription products; Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 4.5/10, high confidence.

Passes 3/7 gates (clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: aggressive.

Val4.2Qual5.7Grw4.8Mom2.9Sent4.9Ins3.8Peer4.4Tech2.8Risk4.04.5OVERALL

Thesis

Rewards
Strong earnings beat streak (3/4)
Earnings estimates trending UP
Risks
Concentration risk — Product: subscription prescription products
Analyst target reached - limited upside remaining
Leverage penalty (D/E 2.1): -1.5

Key Metrics

P/E (TTM)51.6
P/E (Fwd)19.1
Mkt Cap$6.1B
EV/EBITDA37.3
Profit Mgn5.5%
ROE25.2%
Rev Growth28.4%
Beta2.31
DividendNone
Rating analysts22

Quality Signals

Piotroski F7/9

Options Flow

P/C1.24bearish
IV105%elevated
Max Pain$5-81.1% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductsubscription prescription products
    10-K Item 1A: 'we derive a substantial majority of our revenue from customers' subscription-based purchases of prescription products made available through our platform'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

52w Position
0.0
Support Resistance
4.1
Bollinger
4.2

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.0
Obv
1.0
Rsi
3.3
Macd
4.0
Ma Position
6.0
Volume distribution (falling OBV)Below 200-MA, MA slope -10.3%/30d — confirmed downtrend
GatesMomentum 2.9<4.5A.R:R -0.9=NEGATIVEDeath cross (50MA < 200MA)EARNINGS PROXIMITY 11d<=14d (soft)Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARSuitability: Aggressive
RSI
67 · Neutral
↑ 20D MA↑ 50D MA↓ 200D MADEATH CROSSSupport $18.75Resistance $31.86

Price Targets

$25
$31
A.Upside+18.2%
A.R:R-0.9:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-13.6% upside)
! NEWS_MOD=+1: SELL_IF_HOLDING → HOLD_IF_HOLDING
! Momentum score 2.9/10 — below 4.5 minimum

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-05-11 (11d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is HIMS stock a buy right now?

Hold if already holding. Not a fresh buy at $26.41, but acceptable to hold if already in. Reasons: Concentration risk — Product: subscription prescription products; Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $31.22 (+18.2%), stop $24.58 (−7.4%), A.R:R -0.9:1. Score 4.5/10, high confidence.

What is the HIMS stock price target?

Take-profit target: $31.22 (+18.1% upside). Target $31.22 (+18.2%), stop $24.58 (−7.4%), A.R:R -0.9:1. Stop-loss: $24.58.

What are the risks of investing in HIMS?

Concentration risk — Product: subscription prescription products; Analyst target reached - limited upside remaining; Leverage penalty (D/E 2.1): -1.5.

Is HIMS overvalued or undervalued?

Hims & Hers Health, Inc. trades at a P/E of 51.6 (forward 19.1). TrendMatrix value score: 4.2/10. Verdict: Hold.

What do analysts say about HIMS?

22 analysts cover HIMS with a consensus score of 3.5/5. Average price target: $26.

What does Hims & Hers Health, Inc. do?Hims and Hers operates a consumer telehealth platform connecting patients to licensed providers for prescription...

Hims and Hers operates a consumer telehealth platform connecting patients to licensed providers for prescription medications and wellness products across sexual health, hair loss, weight loss, dermatology, and mental health. Revenue reached 2,347.6M in 2025, driven primarily by subscription purchases of prescription products fulfilled through wholly-owned pharmacies.

Related stocks: NBIX (Neurocrine Biosciences, Inc.) · INDV (Indivior Pharmaceuticals, Inc.) · BCRX (BioCryst Pharmaceuticals, Inc.) · COLL (Collegium Pharmaceutical, Inc.) · ANIP (ANI Pharmaceuticals, Inc.)